Loading
Led the imatinib trial in GIST that proved a targeted drug could melt away a solid tumour, and every GIST kinase inhibitor since.
George Demetri led the 2002 trial showing imatinib produces responses in more than half of patients with KIT-positive metastatic GIST, the first proof that a kinase inhibitor could transform a solid tumour and a founding result for precision oncology. He then led the pivotal trials of sunitinib, regorafenib and ripretinib in GIST and of trabectedin and eribulin in soft-tissue sarcoma. He co-directs the Ludwig Center at Harvard.
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST) and the tags gist, sarcoma.
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST) and the tags gist, targeted-therapy.
Shares Dana-Farber Brigham Cancer Center, Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, targeted-therapy.
Shares KIT, Imatinib, Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors.
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST) and the tag gist.
Shares Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors and the tag sarcoma.
Shares Gastrointestinal stromal tumour (GIST), Imatinib and the tag gist.
Shares KIT, Imatinib, Sarcomas (soft tissue, bone, GIST).